Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts

Chest

Volumn 150, Issue 4, 2016, Pages 799-810

  Corren, Jonathan ^a   Weinstein, Steven ^b   Janka, Lindsay ^c   Zangrilli, James ^c   Garin, Margaret ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Allergy and Asthma Specialists Medical Group   (United States)

^c Teva Pharmaceuticals Inc   (United States)

Author keywords

asthma; eosinophil; phase 3; reslizumab

Indexed keywords

PLACEBO; RESLIZUMAB; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MONOCLONAL ANTIBODY;

ACUTE SINUSITIS; ADULT; ALLERGIC RHINITIS; ARTHRALGIA; ASTHMA; BACKACHE; BRONCHITIS; CONFERENCE PAPER; CONTROLLED STUDY; CONTUSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EOSINOPHIL; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HUMAN; HUMAN CELL; INFLUENZA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRAL GASTROENTERITIS; CLINICAL TRIAL; COMPLICATION; EOSINOPHILIA; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; DOUBLE-BLIND METHOD; EOSINOPHILIA; EOSINOPHILS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84994509864     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.03.018     Document Type: Conference Paper

References (27)

1. 1 Global Initiative for Asthma. (GINA report) Global Strategy for Asthma Management and Prevention. 2014.
2. 2 Haldar, P., Pavord, I.D., Shaw, D.E., et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 178:3 (2008), 218–224.
3. 3 Bousquet, J., Chanez, P., Lacoste, J.Y., et al. Eosinophilic inflammation in asthma. N Engl J Med 323:15 (1990), 1033–1039.
4. 4 Garcia, G., Taillé, C., Laveneziana, P., Bourdin, A., Chanez, P., Humbert, M., Anti-interleukin-5 therapy in severe asthma. Eur Respir Rev 22:129 (2013), 251–257.
5. 5 Malinovschi, A., Fonseca, J.A., Jacinto, T., Alving, K., Janson, C., Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 132:4 (2013), 821–827.e1 5.
6. 6 Zeiger, R.S., Schatz, M., Li, Q., et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. J Allergy Clin Immunol Pract 2:6 (2014), 741–750.
7. 7 Takatsu, K., Nakajima, H., IL-5 and eosinophilia. Curr Opin Immunol 20:3 (2008), 288–294.
8. 8 Walsh, G.M., Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther 11:3 (2009), 329–336.
9. 9 Egan, R.W., Athwal, D., Bodmer, M.W., et al. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung 49:9 (1999), 779–790.
10. 10 Kips, J.C., O'Connor, B.J., Langley, S.J., et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167:12 (2003), 1655–1659.
11. 11 Castro, M., Mathur, S., Hargreave, F., et al., Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 184:10 (2011), 1125–1132.
12. 12 Castro, M., Zangrilli, J., Wechsler, M.E., et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3:5 (2015), 355–366.
13. 13 Bjermer, L., Lemiere, C., Maspero, J., et al. A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. Eur Respir J, 44, 2014, P299.
14. 14 Juniper, E.F., O'Byrne, P.M., Guyatt, G.H., Ferrie, P.J., King, D.R., Development and validation of a questionnaire to measure asthma control. Eur Respir J 14:4 (1999), 902–907.
15. 15 Mikulskis, A., Yeung, D., Subramanyam, M., Amaravadi, L., Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. J Immunol Methods 365:1-2 (2011), 38–49.
16. 16 Qiu, Z.J., Ying, Y., Fox, M., et al. A novel homogeneous Biotin–digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum. J Immunol Methods 362:1-2 (2010), 101–111.
17. 17 Gupta, S., Devanarayan, V., Finco, D., et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal 55:5 (2011), 878–888.
18. 18 Shankar, G., Devanarayan, V., Amaravadi, L., et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 48:5 (2008), 1267–1281.
19. 19 Westerhof, G.A., Korevaar, D.A., Amelink, M., et al. Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. Eur Respir J 46:3 (2015), 688–696.
20. 20 Fowler, S.J., Tavernier, G., Niven, R., High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. J Allergy Clin Immunol 135:3 (2015), 822–824.e2.
21. 21 Miranda, C., Busacker, A., Balzar, S., Trudeau, J., Wenzel, S.E., Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 113:1 (2004), 101–108.
22. 22 Louis, R., Lau, L.C., Bron, A.O., Roldaan, A.C., Radermecker, M., Djukanović, R., The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 161:1 (2000), 9–16.
23. 23 Ulrik, C.S., Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthma. Clin Exp Allergy 25:9 (1995), 820–827.
24. 24 Castro, M., Wenzel, S.E., Bleecker, E.R., et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2:11 (2014), 879–890.
25. 25 Ortega, H.G., Liu, M.C., Pavord, I.D., et al., MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371:13 (2014;25), 1198–1207.
26. 26 Haldar, P., Brightling, C.E., Hargadon, B., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360:10 (2009), 973–984.
27. 27 Pavord, I.D., Korn, S., Howarth, P., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380:9842 (2012), 651–659.